Day One Biopharmaceuticals, Inc. (DAWN) scores 47 out of 100 on boothcheck's 11-model valuation framework. Verdict: Avoid The estimated fair value is $12.04, representing a 44% premium to fair value. Quantitative score: 61/100. Qualitative score: 30/100.
Analysis includes bear, base, and bull fair value targets using DCF, Graham, regression, and 8 other valuation models.